ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Trial Profile

ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Nivolumab (Primary) ; Rucaparib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms ATHENA
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 26 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 26 Feb 2018 According to a Clovis Oncology media release, this trial is a part of a broad clinical collaboration with Bristol-Myers Squibb and is expected to begin in the first half of 2018.
    • 01 Nov 2017 According to a Clovis Oncology media release, this trial is expected to begin in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top